SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXANE-2-YL)PYRAZOLO[1.5-A]PYRIMIDINE AND IMIDAZO[1.2-B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS Russian patent published in 2022 - IPC C07D487/04 C07D519/00 A61K31/519 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to a compound of the formula (I) or its pharmaceutically acceptable salt, where: if X is N, Y is C, a compound of the formula (Ia) was obtained, if X is C, Y is N, a compound of the formula (Ib) was obtained. Values of radicals are as follows: L is selected from -(CR^C1R^D1)_u-, -(CR^C1R^D1)_uNR^A1(CR^C1R^D1)_t-, (CR^C1R^D1)_uC(O)NR^A1(CR^C1R^D1)_t-, -(CR^C1R^D1)_uNR^A1C(O)(CR^C1R^D1)_t-, (CR^C1R^D1)_uS(O)_rNR^A1(CR^C1R^D1)_t-, and -(CR^C1R^D1)_uNR^A1S(O)_r(CR^C1R^D1)_t-; R¹ is selected from aryl and heteroaryl, wherein aryl and heteroaryl each is unsubstituted or substituted with at least one substitute independently selected from R^X; each R² is hydrogen, halogen; R³ is selected from C_1-10 alkyl, C_3-10 cycloalkyl, C_3-10 cycloalkyl-C_1-4 alkyl, heterocyclyl, heterocyclyl-C_1-4 alkyl, aryl, aryl-C_1-4 alkyl, heteroaryl, heteroaryl-C_1-4 alkyl, -NR^A3R^B3, -OR^A3, -C(O)R^A3, and -C(O)NR^A3R^B3, wherein alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each unsubstituted or substituted with at least one substitute independently selected from R^X; R⁴ is selected from hydrogen, halogen, C_1-10 alkyl, CN, NO₂; each R^A1, R^A3, R^B3 is independently selected from hydrogen, C_1-10 alkyl, C_3-10 cycloalkyl, C_3-10 cycloalkyl-C_1-4 alkyl, C_3-10 heterocyclyl, heterocyclyl-C_1-4 alkyl, aryl, aryl-C_1-4 alkyl, heteroaryl, and heteroaryl-C_1-4 alkyl, wherein alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each unsubstituted or substituted with at least one substitute independently selected from R^X; or each R^A3 and R^B3, together with an atom(s), to which they are attached, form a heterocyclic ring of 4-12 elements, containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen, and phosphorus, and optionally substituted with 1, 2, or 3 R^X groups; each R^X is independently selected from hydrogen, C_1-10 alkyl, C_3-10 cycloalkyl, aryl, halogen, CN, NO₂, -(CR^c1R^d1)_tOR^b1, -(CR^c1R^d1)_tOC(O)R^b1, wherein alkyl, aryl each is unsubstituted or substituted with at least one substitute independently selected from R^Y; each R^b1 is independently selected from hydrogen, C_1-10 alkyl; each R^Y is independently selected from C_1-10 alkyl, halogen, CN, NO₂; n is 0, 1, 2; each r is 1 and 2; each t is 0; each u is 0. A group of individual compounds, a pharmaceutical composition, and use of the compound are also proposed.

EFFECT: proposed compound has inhibitory activity against protein tyrosine kinase TRK, and it can be used for the treatment or prevention of conditions responding to TRK inhibition.

18 cl, 2 tbl, 43 ex